Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 15/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30121092 | 1.00 | ERN1 (0.50) | ERN1TRIM24TYRTRIM33SMN1; SMN2 | |
| SCHEMBL5882331 | 0.85 | ERN1 (0.49) | ERN1TRIM24TYRTRIM33CA1 | |
| SCHEMBL31355236 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2CA1CA2CDC25B | |
| SCHEMBL7285302 | 0.83 | ERN1 (0.62) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL28292328 | 0.78 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL3645435 | 0.78 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL28282933 | 0.78 | ERN1 (0.56) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL18341497 | 0.78 | NPC1 (0.53) | SMN1; SMN2CA1CA2CDC25B | |
| SCHEMBL548189 | 0.77 | TRIM24 (0.61) | ERN1TRIM24TYRTRIM33SMN1; SMN2 | |
| SCHEMBL29955976 | 0.77 | TRIM24 (0.61) | ERN1TRIM24TYRTRIM33SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112921308-B | Chemical nickel plating process for crystalline silicon heterojunction solar battery | 广州三孚新材料科技股份有限公司 | 2022-08-16 | — | — | CN | claimed |
| CN-112921308-A | Chemical nickel plating process for crystalline silicon heterojunction solar battery | 广州三孚新材料科技股份有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-115279730-B | 2, 5-Or 2, 6-disubstituted hydroquinone derivatives having at least one carboxyl, sulfo or amido group, useful as medicaments | OM药物公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4118069-B1 | PARA-HYDROQUINONE DERIVATIVES AS VEGF, TNF AND/OR IL INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES | OM PHARMA SA (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| EP-4118069-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2023-01-18 | — | — | EP | disclosed |
| CN-115279730-A | 2, 5-or 2, 6-disubstituted hydroquinone derivatives having at least one carboxyl, sulfo or amido group useful as medicaments | OM药物公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-112921308-B | Chemical nickel plating process for crystalline silicon heterojunction solar battery | 广州三孚新材料科技股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-112921308-B | Chemical nickel plating process for crystalline silicon heterojunction solar battery | 广州三孚新材料科技股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2021180655-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021180655-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2021-09-16 | — | — | WO | disclosed |
| EP-3878837-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2021-09-15 | — | — | EP | disclosed |
| CN-112921308-A | Chemical nickel plating process for crystalline silicon heterojunction solar battery | 广州三孚新材料科技股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-112921308-A | Chemical nickel plating process for crystalline silicon heterojunction solar battery | 广州三孚新材料科技股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | HRH4, NCOA4, HRH3 | ERN1 3058/4885TRIM24 1892/4885TYR 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.